CN116355076A - 一种重组多肽及其制备方法和应用 - Google Patents
一种重组多肽及其制备方法和应用 Download PDFInfo
- Publication number
- CN116355076A CN116355076A CN202211593323.7A CN202211593323A CN116355076A CN 116355076 A CN116355076 A CN 116355076A CN 202211593323 A CN202211593323 A CN 202211593323A CN 116355076 A CN116355076 A CN 116355076A
- Authority
- CN
- China
- Prior art keywords
- collagen
- polypeptide
- recombinant polypeptide
- recombinant
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 48
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000588724 Escherichia coli Species 0.000 claims abstract description 16
- 230000021164 cell adhesion Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 abstract description 58
- 102000008186 Collagen Human genes 0.000 abstract description 55
- 229920001436 collagen Polymers 0.000 abstract description 55
- 230000000694 effects Effects 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910001453 nickel ion Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010036236 extracellular matrix receptor Proteins 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- -1 tissue engineering Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
一种重组多肽及其制备方法和应用,属于基因工程技术领域,具体公开了一种人源性III型重组胶原多肽及其制备方法和用途。本发明涉及的重组多肽序列如SEQ ID No.2或SEQ IDNo.5所示,其可在大肠杆菌中表达,并具有较好的细胞粘附活性。
Description
技术领域
本发明属于基因工程技术领域,涉及一种重组多肽及其制备方法和用途。
背景技术
胶原蛋白是生物高分子,动物结缔组织中的主要成分,也是哺乳动物体内含量最多、分布最广的功能性蛋白,占蛋白质总量的25%~30%,某些生物体甚至高达80%以上,因具有良好的生物相容性、可生物降解性以及生物活性,因此在食品、医药、组织工程、化妆品等领域获得广泛的应用。同时,胶原作为细胞外基质的主要组分,不仅起到物理的支架结构,同时还可通过细胞外基质受体分子与细胞间实现信号传递,参与调控细胞的行为。
从结构上讲,胶原由三个自身按左螺旋排列的多肽链构成,肽链中含有大量甘氨酸、脯氨酸和羟脯氨酸,三条相互独立的胶原蛋白肽链依靠甘氨酸之间形成的氢键维系三股螺旋相互缠绕的结构。众多胶原蛋白大分子又可彼此并排形成纤维互相交联的结构,使最终产物具备较高机械强度。胶原的三重螺旋结构[(Gly-X-Y)n重复序列]是其特有的活性构象,众多胶原蛋白大分子彼此并排形成纤维互相交联的结构,该结构使胶原蛋白具备高拉伸强度,能够更稳定的在生物体内发挥支撑作用。此外,前胶原蛋白在成熟为原胶原蛋白之前经历了几次翻译后修饰,原胶原蛋白可以交联成胶原纤维。这些翻译后修饰对于确保三个单链前胶原分子相互结合形成异三聚体或同源三聚体原胶原至关重要。只有热稳定的原胶原蛋白才能相互结合,形成胶原纤维,最后形成胶原纤维。特别是,脯氨酸到羟脯氨酸的羟基化对于确保三螺旋前胶原的热稳定性是至关重要的。
尽管胶原蛋白用途广泛,但目前医学界使用的胶原蛋白大多是动物来源的,以胶原蛋白的氨基酸组成而言:哺乳动物猪、牛与人的相似度为95%,鱼与人的相似度65%。虽然哺乳动物猪、牛等与人的胶原蛋白相似度较高,其仍然难以避免病毒感染以及致敏性的危险。而食用鱼类所萃取的胶原蛋白人体的利用率低于65%,无法完全被人体吸收与利用。所以其常用于食品运用,少部分运用于化妆品,但无法被用于医疗器材或较精密的组织工程产品。所以,目前的胶原蛋白只能在化妆品和保健品中使用,根本无法发挥胶原蛋白的原本生物学功能。因此,鉴于对胶原蛋白的高需求,有必要开发新的方法来以一致和高效的方式大量生物生产重组胶原蛋白。基因工程制备方法能尽可能的降低免疫原性,更好的控制致病病毒传播的风险,避免掉提取残留的酸、碱等溶剂带来的细胞毒性,还具备可加工性(如水溶性和乳化特性)、质量稳定可控等优点。
发明内容
本发明的目的是提供一种重组人源胶原多肽及其制备方法。
本发明是通过以下技术方案实现的:
一种重组人源胶原多肽,基本重复单元为:GFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMGPR(SEQ ID No.1),为人III型胶原蛋白核心肽段。
进一步地,上述的重组人源胶原多肽为C303-1,包括氨基酸360个,基本重复单元为:GFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMGPR,为人III型胶原蛋白核心肽段,以pET-22b作为质粒载体,氨基酸序列如下:
所述人源胶原多肽C303-1的DNA序列如下:
进一步地,重组人源胶原多肽C303-2,包括氨基酸369个,为C303-1多肽C端再连接氨基酸序列为GAPGPCCGG的多肽(SEQ ID No.4),该序列为人III型胶原蛋白核心肽段及肽尾段,以pET-28a作为质粒载体,序列如下:
所述人源胶原多肽C303-2的DNA序列如下:
本发明还提供了编码上述重组III型人源化胶原蛋白多肽的多核苷酸。其核苷酸序列如SEQ ID No.3或SEQ ID No.6所示。
本发明还提供了包含上述多核苷酸的表达载体。
本发明还提供了包含上述述表达载体的宿主细胞,所述宿主细胞是大肠杆菌。
所述的重组人源胶原多肽的制备方法,包括如下步骤:
(1)大肠杆菌基因工程菌的构建;
(2)大肠杆菌基因工程菌的发酵培养;
(3)重组人源胶原多肽的诱导和表达;
(4)重组人源胶原多肽的纯化。
其中,
所述步骤(1)中,所述大肠杆菌基因工程菌的构建,步骤如下:(1)优化选择人的III型胶原蛋白基因螺旋区的DNA片段,针对大肠杆菌偏好进行密码子优化后将基因进行合成,得到完整的目的基因;(2)将目的基因连接至合适质粒中,并转入大肠杆菌表达菌株中,筛选得到大肠杆菌基因工程菌。
所述步骤(2)中,所述大肠杆菌基因工程菌的发酵培养,步骤如下:(1)挑取优选后的大肠杆菌基因工程菌单菌落,于4ml的LB培养基中37℃培养过夜;(2)将菌液按照1:100接种放大培养,37℃培养3-4小时,加入0.1mM IPTG进行诱导,16℃继续培养20小时,离心收集菌体。
所述步骤(3)中,所述重组人源胶原多肽的纯化,步骤如下:(1)用裂解液重悬细菌,超声破碎,离心收集上清液;(2)利用镍离子亲和柱从上清液中纯化得到重组多肽;(3)将重组多肽冻干或者制成溶液。
本发明提供一种组合物,其包含所述的III型人源化胶原蛋白多肽。所述组合物是药物组合物、医疗器械、组织工程产品、化妆品或保健品。
本发明提供所述组合物在制备具有促进细胞黏附作用的产品中的用途。
本发明提供了上述重组III型人源化胶原蛋白多肽在制备具有促进细胞黏附作用的产品中的用途。
与现有技术相比,本发明具有以下特点:
(1)本发明能尽可能的降低动物来源的胶原蛋白的免疫原性,更好的控制致病病毒传播的风险,避免掉提取残留的酸、碱等溶剂带来的细胞毒性,还具备可加工性(如水溶性和乳化特性)、质量稳定可控等优点;
(2)本发明选择的III型胶原蛋白序列为通过分析筛选优化所得的序列;
(3)采用大肠杆菌表达系统,适于大规模放大,生产成本较低且生产效率高效,而且基因中的序列针对大肠杆菌表达系统进行了密码子优化,进一步提高了产量;
(4)生产的重组胶原多肽具有非常好的亲水性和稳定性,其氨基酸组成与天然胶原蛋白氨基酸序列相应部分100%相同,应用于人体不会产生免疫排斥和过敏反应,可以广泛应用于生物医药和化妆品行业;
(5)本发明产品经过活性检测,具有较好的粘附活性,可以在人体中行使天然蛋白的功能。
附图说明
图1为本发明重组多肽C303-1、C303-2纯化后蛋白电泳图;
图2为本发明重组多肽C303-1、C303-2细胞黏附活性检测结果。
具体实施方式
下面通过具体实施例,对本发明的技术方案作进一步具体的说明,但是本发明并不限于这些实施例。
本发明通过合成人源性III型重组胶原蛋白基因,经过一系列的酶切、连接、转化,使其在大肠杆菌Rosetta(DE3)菌株中得以表达。
LB培养基:0.5%酵母提取物、1%蛋白胨与1%氯化钠(如配置固体培养基,在灭菌前加入1.5%琼脂),115℃高压灭菌30min。
作为最优的实施过程,以下仅列举选用氨基酸序列如SEQ ID No.2所示的胶原多肽C303-1进行具体实施。
实施例1:C303-1基因表达载体的构建及表达
(1)人源胶原多肽C303-1全长基因序列经过密码子优化后如下所示:
C303-1基因全长1080bp,利用PCR的方法克隆扩增此DNA片段,琼脂糖凝胶电泳回收目的基因。利用引物上加入的NcoⅠ和XhoⅠ的酶切位点,加入相应的限制性内切酶将基因片段切成粘性末端,并与相应酶切处理过的pET22b的表达载体共孵育,加入T4 DNA连接酶,16℃连接4小时,转化大肠杆菌Rosetta(DE3);用氨苄青霉素钠和氯霉素双抗性-LB平板筛选挑出阳性克隆,利用菌落PCR的方法鉴定阳性克隆正确,最后测序确定重组质粒含有正确的基因序列阅读框架,构建成功pET22b-C303-1重组表达载体。
(2)挑取正确的大肠杆菌阳性克隆,在4ml LB培养基中培养过夜,按照1:100转接,在摇瓶中37℃培养至OD600为0.4-0.6,按照终浓度为0.1mM加入IPTG诱导表达,16℃培养20小时,离心收集菌体,保存于-20℃或者立即进入下步纯化。
(3)用生理盐水洗涤混合后的菌体沉淀,用20-30ml体积重悬约400ml菌液沉淀,用溶菌酶配合Triton X-100帮助裂解细菌(可选),在冰水混合物环境下超声破菌(5s超声,5s间歇,全长10min,保护温度44℃),12000rpm/min离心20min,收集上清液。此时溶液中即含有大量的C303-1重组胶原多肽。
(4)用lysis buffer清洗镍离子亲和柱(Ni-NTAHis-Bind Resin)柱材,然后将柱材和C303-1的溶液混合共育,室温或冰上轻摇30min,然后上柱,用含有10mM咪唑的PBS缓冲液洗涤杂蛋白,再用含有300mM咪唑的PBS缓冲液洗涤目的蛋白C303-1,所得产物透析过夜,冻干为干粉待用。
(5)所得胶原多肽利用SDS-PAGE检测纯度。具体过程为:取纯化后的蛋白液8μl,加入2μl 5X的蛋白上样缓冲液(250mM的Tris-HCl(pH:6.8),10%SDS,0 5%溴酚蓝,50%甘油,巯基乙醇),置于100℃沸水中煮10min,然后每孔10μl加入SDS-PAGE蛋白胶中,电压80V跑2h后,用考马斯亮蓝染色液(0.1%考马斯亮蓝R-250,25%异丙醇,10%冰醋酸)进行蛋白染色20min,再利用蛋白脱色液(10%醋酸,5%乙醇)进行脱色。最后与人天然胶原蛋白相对照测量蛋白活性。
结果:
图1的电泳图表明得到表观分子量35.4kDa的C303-1,分子量分别对应于SEQ IDNo.2的氨基酸序列的多肽。
实施例2:C303-1及C303-2蛋白检测活性
胶原多肽的活性检测方法参考文献Juming Yao,Satoshi Yanagisawa,TetsuoAsakura,Design,Expression and Characterization of Collagen-Like ProteinsBased on the Cell Adhesive and Crosslinking Sequences Derived from NativeCollagens,J Biochem.136,643-649(2004)的方法。具体实施方法如下:
(1)利用紫外吸收法检测待测蛋白样品的浓度,包括对照人胶原多肽,重组C303-1和C303-2蛋白样品。具体为,分别测定样品在215nm和225nm下的紫外光吸收,利用经验公式C(μg/mL)=144X(A215-A225)计算蛋白质浓度,注意需在A215<1.5的情况下检测。该方法的原理是测定肽键在远紫外光下的特征吸收,不受生色团含量的影响,干扰物质少,操作简便,适合检测考马斯亮蓝不显色的人胶原蛋白及其类似物。(参考文献为Walker JM.TheProtein Protocols Handbook,second edition.Humana Press.43-45.)检测完蛋白浓度后,用PBS将所有待测蛋白浓度调整到0.5mg/ml。
(2)向96孔板中加入100μl各种蛋白溶液和空白PBS溶液对照,4℃静置过夜。
(3)每孔用PBS清洗2次。
(3)每孔中加入4*104个培养状态良好的3T3细胞,37℃孵育25min。
(4)每孔用PBS清洗2次。
(5)用CCK8试剂盒检测OD450nm的吸光度。根据空白对照的数值,可以计算出细胞的贴壁程度。细胞的贴壁率即可以反应胶原多肽的活性。蛋白的活性越高,越能在短时间给细胞提供优质的外环境,帮助细胞贴壁。
结果参见图2。
图2的结果表明,人重组胶原多肽C303-1和C303-2与商品化的人胶原多肽相比,皆具有很好的黏附活性。
Claims (10)
1.一种重组多肽,其特征在于,所述重组多肽的氨基酸序列如SEQ ID No.2或SEQ IDNo.5所示。
2.编码权利要求1所述重组多肽的多核苷酸,其特征在于,所述核苷酸序列如SEQ IDNo.3或SEQ ID No.6所示。
3.表达载体,其特征在于,包含权利要求2所述的多核苷酸。
4.宿主细胞,其特征在于,包含权利要求3所述的表达载体。
5.根据权利要求4所述的宿主细胞,其特征在于,所述宿主细胞是大肠杆菌。
6.一种权利要求1所述的重组多肽的制备方法,其特征在于,包括以下步骤:
(1)在培养基中培养根据权利要求4或5所述的宿主细胞并制备重组多肽;
(2)收获并纯化多肽;
(3)将多肽冻干或者制成溶液。
7.一种组合物,其特征在于,包含权利要求1所述的重组多肽。
8.根据权利要求7所述的组合物,其特征在于,所述组合物是药物组合物、医疗器械、组织工程产品、化妆品或保健品。
9.权利要求1所述的重组多肽在制备具有促进细胞粘附作用的产品中的用途。
10.权利要求7或8所述的组合物在制备具有促进细胞黏附作用的产品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211593323.7A CN116355076A (zh) | 2022-12-13 | 2022-12-13 | 一种重组多肽及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211593323.7A CN116355076A (zh) | 2022-12-13 | 2022-12-13 | 一种重组多肽及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116355076A true CN116355076A (zh) | 2023-06-30 |
Family
ID=86929829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211593323.7A Pending CN116355076A (zh) | 2022-12-13 | 2022-12-13 | 一种重组多肽及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116355076A (zh) |
-
2022
- 2022-12-13 CN CN202211593323.7A patent/CN116355076A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110606896B (zh) | 重组人源III型胶原蛋白α1链及其应用 | |
CN113621052B (zh) | 一种重组i型人源化胶原蛋白多肽及其制备方法和用途 | |
KR102559311B1 (ko) | 재조합 인간 xvii형 콜라겐, 제조방법 및 응용 | |
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN103122027B (zh) | 一种重组人源胶原蛋白及其生产方法 | |
CN109575126B (zh) | 多肽、其生产方法和用途 | |
CN113683679B (zh) | 一种重组i型人源化胶原蛋白c1l6t及其制备方法和用途 | |
CN113621053A (zh) | 一种重组人源胶原蛋白及其制备方法和应用 | |
CN110724187B (zh) | 一种高效表达利拉鲁肽前体的重组工程菌及其应用 | |
CN110903383A (zh) | 一种重组人源i型胶原蛋白、编码基因、工程菌及其应用 | |
CN113683680A (zh) | 一种重组ⅰ型人源化胶原蛋白c1l1t及其制备方法和用途 | |
JPH0797995B2 (ja) | ペプチド類の製造法 | |
CN112980865A (zh) | 一种重组类人胶原蛋白工程菌的构建方法 | |
CN114409807B (zh) | 一种稳定的大分子i型重组胶原蛋白及其用途 | |
CN116554309A (zh) | 一种重组人源ⅲ型胶原蛋白及其制备方法和应用 | |
CN117025559A (zh) | 重组脯氨酸羟化酶、羟基化重组胶原蛋白及其制备方法与应用 | |
CN112500495A (zh) | 一种elp-ⅲ型胶原蛋白的纯化方法及应用 | |
CN116355076A (zh) | 一种重组多肽及其制备方法和应用 | |
CN110540601B (zh) | 重组PLB-hEGF融合蛋白及其应用 | |
CN101608179B (zh) | 融合肝素酶及其编码基因 | |
CN118085064A (zh) | 一种重组多肽及其制备方法 | |
CN116948014B (zh) | 生物合成人体结构性材料vi型胶原蛋白的方法 | |
CN116789804B (zh) | 一种生物合成人体结构性材料的制备方法 | |
CN117466992B (zh) | 一种纤连蛋白突变体及其制备和应用 | |
CN117756926B (zh) | 一种重组ⅩⅦ型胶原蛋白Pro.C17及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |